Insmed’s story now hinges on whether a new treatment can reach patients soon and expand into several related lung and sinus conditions, which could change how the company grows over the next few years. The big question is whether regulators, insurers, and real-world patient use line up with the optimistic expectations being set for the launch.Read more
Insmed’s new bronchiectasis pill shows early momentum, but the next phase depends on cautious lung doctors and on finding many more patients who are still going undiagnosed. With more studies and approval decisions ahead across its pipeline, the path to longer-term growth could be bumpier than the market expects.Read more
Insmed is building momentum in lung disease treatments, with one key medicine gaining traction and several others aiming to reach far more patients over time. The big question is whether insurance access, doctor adoption, and late-stage trial results keep moving in the right direction—or slow the story down.Read more
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
